Therapeutic treatment of chronic myelogenous leukemia by administration of 2-chloro-2'-deoxy adenosine
AssigneeThe Scripps Research Institute
InventorErnest Beutler
Life of this patent
Estimating the term…
Abstract
A process for the treatment of chronic myelogenous leukemia in mammals is disclosed that utilizes a 2-halo-2'-deoxyadenosine derivative as the active treating agent.
Claims8
A process for treating chronic myelogenous leukemia that comprises administering to a host mammal having chronic myelogenous leukemia a therapeutically effective amount of a substituted adenosine derivative as an active ingredient dissolved or dispersed in a pharmacologically acceptable carrier, said adenosine derivative having a structure represented by the formula:
- ##STR7## wherein Y is halogen, and X is hydrogen.
A process for treating chronic myelogenous leukemia that comprises administering to a human having chronic myelogenous leukemia an amount of about 0.04 to about 1.0 milligrams per kilogram of body weight of a substituted adenosine derivative as an active ingredient dissolved or dispersed in a pharmacologically acceptable carrier, said adenosine derivative having a structure represented by the formula:
- ##STR8## wherein X is hydrogen or fluoro.
Dependencies are inferred from the claim text.